Hubei Guangji Pharmaceutical Co Ltd

Hubei Guangji Pharmaceutical Co Ltd has a debt-to-equity ratio of 1.29, indicating a moderate reliance on debt financing, and a current ratio of 1.01, suggesting limited short-term liquidity cushion. The company's liquidity position is assessed as medium risk, with negative net cash after subtracting total debt, signaling potential short-term cash flow constraints.

Profitability metrics are weak, with a return on equity of -4.48% and a return on assets of -1.8%, both significantly below the typical performance of the pharmaceutical industry. These figures indicate that the company is not generating returns for shareholders or effectively utilizing its assets.

The company's revenue is concentrated in a single geographic market, China, with no disclosed international operations. This lack of geographic diversification increases exposure to domestic regulatory, economic, and competitive pressures.

The company's revenue in the latest period was 116.3 million CNY, compared to an analyst estimate of 843.8 million CNY, suggesting a significant underperformance. The outlook for the current fiscal year indicates a negative growth trajectory, with no clear signs of improvement in the near term.

The company's risk profile includes medium liquidity risk and low dilution risk. The negative operating cash flow of -114.7 million CNY and capital expenditure of -99.0 million CNY suggest ongoing operational and investment challenges. No significant dilution sources are identified in the latest filings.

Recent financial filings show a net loss of 56.1 million CNY, with operating income also negative at -59.9 million CNY. These results reflect ongoing operational inefficiencies and cost pressures. No recent earnings call transcripts or major strategic announcements have been disclosed.

Hubei Guangji Pharmaceutical Co Ltd (000952.SZ) has been formally classified within the Healthcare economic sector, with its primary activity identified as Pharmaceuticals. This taxonomic update provides a clearer structural definition of the company’s operational focus, aligning its profile with industry-specific benchmarks for the healthcare sector. Concurrently, the company’s risk assessment framework has been initialized with specific metrics. Dilution risk is now rated as low, indicating a stable capital structure with minimal immediate threat of share value erosion from new issuances. This assessment suggests that existing shareholders face limited pressure from equity dilution in the near term. Liquidity risk, however, is assessed at a medium level. This classification highlights potential constraints or variability in the company’s ability to meet short-term financial obligations, warranting closer monitoring of cash flow dynamics and working capital management relative to its pharmaceutical operations. These updates establish a foundational baseline for analyzing Hubei Guangji Pharmaceutical, moving from undefined fields to specific risk and sector classifications. The combination of low dilution risk and medium liquidity risk offers investors a nuanced view of the company’s financial stability and operational categorization within the broader healthcare market.

Net income surged 127.2% year-over-year to CNY 110.1 million, signaling a strong operational turnaround.

Free cash flow improved by 117.7% to CNY 64.8 million, demonstrating significant recovery in cash generation.

Cash conversion ratio of 2.04 ranks in the top quartile among 862 pharmaceutical peers.

Revenue grew 25.9% year-over-year to CNY 785.6 million, reversing a four-year decline trend.

Long-term debt decreased to CNY 378.3 million, down from CNY 1.4 billion in the prior year.

Debt-to-equity ratio of 1.29 is significantly higher than the peer median of 0.18.

The company faces high credit risk, indicating potential difficulties in meeting financial obligations.

Revenue ¥163.1M, +9,8% YoY; Operating income +14,1% YoY.

• ▍Revenue ¥163.1M, +9,8% YoY
• ▍Operating income +14,1% YoY
• ▍Net income +12,8% YoY
• ▍Net margin -19.4%

Revenue ¥194.7M, +10,2% YoY; Operating income −129,8% YoY.

• ▍Revenue ¥194.7M, +10,2% YoY
• ▍Operating income −129,8% YoY
• ▍Net income −124,7% YoY
• ▍Net margin -157.8%

Revenue ¥144.9M, −12,6% YoY; Operating income +56,8% YoY.

• ▍Revenue ¥144.9M, −12,6% YoY
• ▍Operating income +56,8% YoY
• ▍Net income +58,0% YoY
• ▍Net margin -15.0%

Revenue ¥135.9M, +16,8% YoY; Operating income +30,6% YoY.

• ▍Revenue ¥135.9M, +16,8% YoY
• ▍Operating income +30,6% YoY
• ▍Net income +30,1% YoY
• ▍Net margin -28.9%

Revenue ¥148.5M; Operating income -¥40.0M.

• ▍Revenue ¥148.5M
• ▍Operating income -¥40.0M
• ▍Net margin -24.4%

Revenue ¥176.6M; Operating income -¥147.4M.

• ▍Revenue ¥176.6M
• ▍Operating income -¥147.4M
• ▍Net margin -77.4%

Revenue ¥624.0M, −2,3% YoY; Operating income −39,3% YoY.

• ▍Revenue ¥624.0M, −2,3% YoY
• ▍Operating income −39,3% YoY
• ▍Net income −37,0% YoY
• ▍Free cash flow −2,8% YoY
• ▍Net margin -64.8%

Revenue ¥638.8M, −13,4% YoY; Operating income −127,1% YoY.

• ▍Revenue ¥638.8M, −13,4% YoY
• ▍Operating income −127,1% YoY
• ▍Net income −110,5% YoY
• ▍Free cash flow +43,6% YoY
• ▍Net margin -46.2%

Revenue ¥737.8M, −7,5% YoY; Operating income −334,2% YoY.

• ▍Revenue ¥737.8M, −7,5% YoY
• ▍Operating income −334,2% YoY
• ▍Net income −378,5% YoY
• ▍Free cash flow −543,5% YoY
• ▍Net margin -19.0%

Revenue ¥797.6M, +1,5% YoY; Operating income −51,6% YoY.

• ▍Revenue ¥797.6M, +1,5% YoY
• ▍Operating income −51,6% YoY
• ▍Net income −54,3% YoY
• ▍Free cash flow −251,1% YoY
• ▍Net margin 6.3%